Key result
Both metoprolol and nipradilol increased left ventricular ejection fraction and reduced cardiac events (both p<0.05) compared to conventional therapy in patients with idiopathic dilated cardiomyopathy.
Why the study?
Does beta-blockade with metoprolol or nipradilol improve symptoms and cardiac function in patients with idiopathic dilated cardiomyopathy?
Does beta-blockade with metoprolol or nipradilol improve symptoms and cardiac function in patients with idiopathic dilated cardiomyopathy?
p-value: p=<0.05
Nonselective beta-blockade with nipradilol is as effective as beta-1-selective metoprolol in improving symptoms and cardiac function in idiopathic dilated cardiomyopathy.
Supports beta-blocker use in idiopathic dilated cardiomyopathy; leaves open comparative efficacy of nipradilol versus metoprolol in randomized trials.
This study investigated the therapeutic efficacy of two different beta-blockers, metoprolol (beta 1-selective) and nipradilol (nonselective) for the treatment of idiopathic dilated cardiomyopathy (DCM). The New York Heart Association functional class improved in the metoprolol group (n = 9) and the nipradilol group (n = 9), but not in the control group who received conventional therapy (n = 8). The left ventricular ejection fraction increased in both the beta-blocker groups (p < 0.01, p < 0.05). Lymphocyte beta-adrenoceptors were upregulated in the nipradilol group (p < 0.01). Cardiac events were less common in both the beta-blocker groups than in the control group (both p < 0.05). Thus, nipradilol improved symptoms and cardiac function with a favorable effect on sympathoneuronal activity as well as metoprolol in patients with DCM. Therefore, beta 1-selectivity is not essential to achieve therapeutic efficacy with beta-blockade therapy for DCM.
No takes yet. Share an insight, caveat, or question.
Yoshikawa et al. (2008) studied Idiopathic dilated cardiomyopathy (n=26). Metoprolol and nipradilol vs. Conventional therapy was evaluated on Cardiac events (p=<0.05). Both metoprolol and nipradilol increased left ventricular ejection fraction and reduced cardiac events (both p<0.05) compared to conventional therapy in patients with idiopathic dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: